Evonik Shares Rally on Strategic Moves and Confirmed Outlook

Evonik shares rise 5% after a 10% MetAMINO price increase, R&D reorganization into an 'Innovation Factory,' and a reaffirmed 2026 EBITDA forecast of €1.7-2.0B.

A combination of strategic pricing power, organizational restructuring, and a reaffirmed financial forecast provided a significant boost to Evonik's stock at the end of the trading week. The chemical company's shares advanced by just over five percent on Friday, positioning it as a top performer within Germany's MDAX index.

Financial Foundation and Forward Guidance

From a financial perspective, Evonik remains on solid ground. The company reported revenue of €14.1 billion for the 2025 fiscal year, with adjusted EBITDA reaching €1.87 billion. Looking ahead to 2026, management has reiterated its guidance, projecting adjusted EBITDA to land between €1.7 billion and €2.0 billion.

A key metric under scrutiny is the return on capital employed (ROCE), which stood at 6.1% for 2025. This figure remains notably below the firm's medium-term target of eleven percent. Market participants are expected to focus closely on progress toward this goal in the coming weeks.

Pricing Initiative Drives Investor Confidence

A primary catalyst for the share price increase was a decisive operational move. Evonik announced a global ten percent price increase for MetAMINO, its DL-methionine product used in animal nutrition. This action is feasible due to current tightening in the market for amino acids and C4 chemicals, an environment that allows the company to pass on higher input costs directly to customers.

This development is particularly significant for Evonik's C4 segment, which endured a cyclical low point in the previous business year. Anticipated recovery in this margin-rich area is adding substantial weight to the current valuation.

Research Unit Overhauled for Speed

Concurrently, Evonik has reorganized its strategic research division. The existing Creavis unit is being replaced by an "Innovation Factory," a new entity designed to bring technological developments—including biopolymers and rhamnolipids—to market maturity within an average timeframe of five years. The market interprets this structural shift as a direct response to mounting pressure from international competitors.

Upcoming Events for Market Scrutiny

Investor attention will now turn to a series of imminent corporate events. Update calls with management are scheduled for March 30th and 31st, where updates on cost-reduction programs and first-quarter performance will likely be the central topics. This will be followed by the Annual General Meeting on June 3rd, where shareholders will vote on a proposed dividend of €1.00 per share.